Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer

Article content

TORONTO, May 17, 2025 (GLOBE NEWSWIRE) — Today, on DIPG Awareness Day, Brain Cancer Canada is pleased to award $68,000 for an innovative research initiative led by Dr. Aru Narendran, MD, PhD, and Dr. Patrick Sipila, PhD, at The University of Calgary and Alberta Children’s Hospital.

Article content

Article content

The project, “Biological Correlative Studies to Improve Current Outcomes of Diffuse Intrinsic Pontine Glioma (DIPG) and High-Risk Brain Tumours with a Neoantigen-Based Anti-Cancer Vaccine in Clinical Trial,” focuses on advancing a novel immunotherapy approach for some of the most aggressive childhood brain cancers. 

Article content

Article content

DIPG is a devastating pediatric brain tumour, with fewer than 10% of children surviving two years post-diagnosis. As DIPG progresses, it severely impacts essential brain functions, making it increasingly difficult for children to see, walk, and even breathe.

Article content

Article content

Current treatment options, including radiation therapy and chemotherapy, offer only temporary or limited benefit, and survival rates have remained largely unchanged for decades, despite broader advances in cancer research. 

Article content

In response to this urgent need, Dr. Narendran and Dr. Sipila’s team are investigating a new anti-cancer vaccine designed to train a patient’s immune system to recognize and eliminate tumour cells. Their research aims to validate the safety, activity, and potential clinical applications of this neoantigen-based immunotherapy. By providing critical biological insights into the vaccine’s effectiveness, the project seeks to accelerate the development of promising new treatment options for children affected by DIPG and other high-risk brain tumours. 

Article content

Dr. Narendran explains, “Every advancement in DIPG research brings renewed hope for the entire brain cancer community. By discovering new and effective treatments, we aim to prove that even the toughest human challenges can be overcome through compassion, collaboration, and innovation. The progress we make today paves the way for tomorrow’s cures, where no child’s future is cut short by a brain cancer.”

Article content

Article content

This groundbreaking work represents an important step toward improving survival outcomes and offering renewed hope to families impacted by these devastating diagnoses. 

Article content

Brain Cancer Canada acknowledges the tremendous contributions of grassroots fundraisers including Trinity’s Army, the $9 Challenge, and Dr. Surya’s 8^th Charity Raffle that have made this award possible.

Article content

Immensely grateful for the support, Dr. Narendran explains the critical need for funding, “Philanthropic organizations such as the Brain Cancer Canada give true hope for children fighting brain cancer, granting the crucial support needed to advance translational research and the preparation of innovative treatment protocols for the future. By funding collaborative efforts and high-risk, high-reward projects, your giving ensures that scientists and physicians continue to work to discover safer, more effective novel treatments for our patients.”

Article content

In recognition of DIPG Day, Brain Cancer Canada is proud to have The Peace Bridge connecting Canada and the U.S., Cabot Tower on Signal Hill in St. John’s, NL, and the CN Tower Toronto, ON, illuminated in yellow. The lighting serves as a powerful symbol of awareness and solidarity in the fight against DIPG.